Access to Innovative Cancer Therapies in 2013 8th Annual Oncology Economics Forum Issues, Challenges & Opportunities Related to Healthcare Reform, Pricing, Reimbursement, and Payer Coverage Decisions in Oncology June 18 & 19, 2013 ● Hyatt Regency Philadelphia at Penn’s Landing ● Philadelphia, PA Day One Agenda - Tuesday, June 18, 2013 7:30 – 8:30 Registration/Check-In and Continental Breakfast 8:30 - 8:35 Welcome & Opening Remarks by Forum Co-Chairs 8:35 – 9:15 Legislative Update and Healthcare Reform Developments Impacting Access to Cancer Care Joseph S. Bailes, MD Medical Oncologist and National Authority on Healthcare Policy The Healthcare Agenda and the Implications for Cancer Care in 2013 and Beyond Sequestration and the Outlook for the Oncology Practice Legislative and Regulatory Update - Exploring Legislative and Regulatory Proposals that Have the Potential to Impact Manufacturers, Pharmacies, PBMs and Health Plans Oncology Coverage and Access Issues 9:15 – 10:00 Health Insurance Exchanges and the Impact of Medicaid Expansion on Biotech/Pharma Caleb DesRosiers, JD Counsel, Health Care Regulatory and Government Strategies Practice, Foley Hoag, LLP With increasing uncertainty created by Medicaid expansion, where do individual states stand and what are the different types of service that will be needed? Competitive opportunities and/or challenges that could result from states’ decisions Understanding the importance of effective relationships with state or federal policy makers 10:00 – 10:30 Morning Break 10:30 – 11:15 Oral Chemotherapy Parity Legislation in the States: The Interaction of Patient Protections and Essential Health Benefits Tim Dube Associate Director, State Public Policy, Genentech Background on oral chemotherapy parity legislative efforts before the ACA Review of federal essential health benefits (EHB) rules and the language on state mandated benefits Review of current state legislative efforts and why advocates have to be mindful of the interaction with EHB www.conferagroup.com ● Tel/ 704.849.6934 1 Access to Innovative Cancer Therapies in 2013 8th Annual Oncology Economics Forum Day One Agenda continued - Tuesday, June 18, 2013 11:15 – 12:00 340B Drug Discount Program Impact on Cancer Care Aaron Vandervelde Principal, Health Analytics, Berkeley Research Group Recent and upcoming activities from HRSA and OPA Need for HRSA to clarify Patient Definition Oversight and compliance considerations, including Medicaid carve in possibilities Oncology site and contract pharmacy expansion 12:00 – 12:30 Health Reform and the Impact on Cancer Care in 2013 How are new policies affecting access to cancer care? What can oncology stakeholders expect in 2013, 2014, and beyond? Joseph S. Bailes, MD Medical Oncologist and National Authority on Healthcare Policy Caleb DesRosiers, JD, MPA, Counsel, Health Care Regulatory an Government Strategies Practice, Foley Hoag, LLP Tim Dube Associate Director, State Public Policy, Genentech Aaron Vandervelde Principal, Health Analytics, Berkeley Research Group _____________________________________________________________________________________________ 12:30 – 1:30 Luncheon _____________________________________________________________________________________________ 1:30 – 2:15 Examining Shifts in Site of Care and Provider Consolidation Donna Bowers, JD, RHIA, CHP Senior Vice President, Cancer Service Line, McKesson Specialty Health Defining the cancer treatment setting: community practices vs. hospitals, integrated cancer networks, and academic institutions Who is “at risk” and how does a community practice remain efficient? Overview of oncology practice alignments and consolidations with comparisons of successes and failures Key considerations to keep in mind before joining a hospital 2:15 – 3:00 Practical Implications of Clinical Pathways in the Oncology Practice Michael Forsyth, RPh Manager, Pharmacy Services, Rocky Mountain Cancer Center Aligning treatment decisions with clinical pathways – quality of care considerations Assessing the economic impact of clinical pathway decisions on the practice Integration of clinical pathways with EMR and IT systems Impact of clinical pathways on the drug selection and purchasing process www.conferagroup.com ● Tel/ 704.849.6934 2 Access to Innovative Cancer Therapies in 2013 8th Annual Oncology Economics Forum One Agenda continued - Tuesday, June 18, 2013 3:00 – 3:30 Afternoon Break 3:30 – 4:00 A Closer Look at an Oncology Clinical Decision Support Platform and the Cancer Treatment Decision Process William Flood, MD Chief Medical Officer, eviti Aligning clinical pathways with evidence-based outcomes and reimbursement objectives The impact of a pathway-based treatment plan review and selection process on the oncology practice Examination of a current oncology clinical decision support platform and the improvement of patient outcomes 4:00 – 4:45 Provider Consolidation, Pathways, Coverage Determinations – A Discussion of the Key Issues Impacting Access to Cancer Care What are the key trends and issues regarding clinical pathways and what is expected in 2013 and beyond? What is on the horizon regarding new treatment platforms? What are the implications for pharma and what role does industry play moving forward? 4:45 – 5:00 Closing Comments 5:00 Forum Adjourns for Day One 5:00 – 6:30 Faculty & Attendee Reception Day Two Agenda - Wednesday, June 19, 2013 7:30 – 8:30 Continental Breakfast 8:30 – 8:45 Opening Remarks and Review of Day One 8:45 – 9:45 Payer Initiatives in the Management of Oncology Joseph S. Bailes, MD Medical Oncologist and National Authority on Healthcare Policy Michael A. Kolodziej, MD, FACP National Medical Director of Oncology Strategy, Office of the Chief Medical Officer, Aetna Bryan Loy, MD Market Medical Officer, Humana - invited Payer perspectives regarding emerging delivery-care models and collaboration efforts with providers Past and current MCO priorities in the specialty drug category Trends impacting payer coverage decisions for oncology www.conferagroup.com ● Tel/ 704.849.6934 3 Access to Innovative Cancer Therapies in 2013 8th Annual Oncology Economics Forum Day Two Agenda continued - Wednesday, June 19, 2013 9:45 – 10:15 Issues & Trends Impacting the Oral Oncology Drug Marketplace Jeff Patton, MD, Founder & CEO, Rain Tree Oncology - invited Oral oncology therapy pilot programs and collaborative efforts Potential payer initiatives in managing the medical benefit versus pharmacy benefit Comparison of specialty pharmacy versus onsite dispensing in oncology 10:15 – 10:45 Morning Break 10:45 – 11:45 Market Access Challenges and Opportunities for Oncology Drugs Coline David Principal, Specialty Drug Market Access Peter W. Davis Partner, Epiphany Partners Outline of reimbursement and pricing trends & exploration of cost controls Regulation of oncology drugs in other markets & outline of global reimbursement and pricing trends Opportunities in emerging markets 11:45 – 12:00 Closing Comments 12:00 Forum Adjourns www.conferagroup.com ● Tel/ 704.849.6934 4